Skip to main content
. 2021 Oct 28;139(12):1794–1806. doi: 10.1182/blood.2021011895

Figure 2.

Figure 2

Responses and uMRD. (A) Best overall response. Response-evaluable patients were defined as having had a pretreatment assessment and ≥1 postbaseline assessment. One patient in the safety population was not evaluable for response. (B) uMRD. MRD-evaluable patients were defined as those with detectable MRD at baseline. Two patients in the response-evaluable population were not evaluable for MRD. nPR, nodular partial response; PR, partial response; uMRD, undetectable minimal residual disease.